Gene therapy's major retreat: From $3.2 million a shot to black‑box warnings — why has a market once valued at hundreds of billions suddenly stalled?

Two headline collapses that changed the narrative

It has been reported that two high‑profile blows in early 2026 crystallized a wider industry rout. BioMarin announced the withdrawal of its A‑type haemophilia gene therapy Roctavian — a product once priced at $2.9–3.2 million and touted as a one‑time cure — after global uptake and revenues fell far short of forecasts. Days later, Sarepta’s chief executive, Doug Ingram, abruptly stepped down as the company struggled under the weight of Elevidys’s safety controversy and a newly added FDA black‑box warning for fatal liver injury. Coincidence? Hardly. These events exposed both the technical fragility and the commercial fragility of an entire field.

From scientific promise to regulatory warning

The trouble runs deep and technical. Most current in‑vivo therapies use adeno‑associated virus (AAV) vectors, which are relatively safe but constrained by limited cargo capacity, uncertain durability and potentially severe immune reactions. Elevidys’s post‑marketing deaths highlighted those immune‑mediated liver risks; similar catastrophic outcomes were seen in earlier AAV trials. It has been reported that the FDA’s tone has shifted from the more permissive era under Peter Marks to a noticeably more cautious posture under new leadership, tightening review standards for riskier platforms and narrowing eligible patient populations. That regulatory tightening raises development time and costs — and investor patience is not infinite.

Commercial realities and the capital cold front

Price and payment collapsed the dream of “one‑and‑done” cures as a viable mass market. A therapy priced at $3.2 million assumes either durable lifetime benefit or payment innovations; in practice, small patient populations, manufacturing complexity and payer resistance have made such business models untenable. Pfizer’s Beqvez and multiple big pharma exits last year underscore that corporate patience ran out long before technologies matured. Capital has rotated away from speculative gene‑therapy bets. Investors now ask blunt questions: does it work reliably, can it be produced at scale, and who will pay? The market’s answer so far has been: not enough.

China: danger, experimentation and a chance to regroup

The overseas chill has rippled into China. Keji Pharmaceutical (科济药业) reportedly saw U.S. manufacturing compliance issues stall its trials, while XinNian Pharmaceuticals (信念医药) — maker of a domestically approved haemophilia B AAV therapy — faces stark payment dilemmas: list price projections and multi‑hundred‑thousand‑dollar patient bills forced it to seek charity discounts and place the drug into local special‑insurance pilots. Geopolitics and export controls complicate cross‑border manufacturing and regulatory paths, even as some skilled personnel return to China after layoffs abroad. The result? A brutal but clarifying winter. Will the survivors be those who can tame AAV’s limits, slash production costs, and forge real reimbursement models — or will gene therapy shrink back into niche, ultra‑expensive interventions? The industry is beginning to get an answer.